Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Pelt – page 15

870 clinical trials in Pelt, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Pelt at a glance
870
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

870 trials in Pelt

Open in trial search

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nucresiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osavampator
  • Sponsor:Neurocrine Biosciences Inc.

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Study of AP31969 compared to placebo to control heart rhythm in patients with atrial fibrillation

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AP31969 sulfate
  • Sponsor:Acesion Pharma ApS

Evaluating Hyperbaric Oxygen Treatment in Addition to Standard Care for Patients with Necrotizing Soft-Tissue Infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Region Hovedstaden

Study of intravenous AOC 1001 to evaluate long-term safety and effectiveness in patients with myotonic dystrophy type 1

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:AOC 1001
  • Sponsor:Avidity Biosciences Inc.

Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Sint Maartenskliniek

Varicella

Recruiting

Study of new chickenpox vaccine and measles-mumps-rubella vaccine given by intramuscular injection in healthy children aged 12 to 15 months

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Study of telisotuzumab adizutecan with osimertinib as first treatment for adults with advanced or metastatic EGFR-mutated non-small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AstraZeneca AB

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Pelt

What the registry says about research in the country

01 Multiple Sclerosis Research

Extensive research focusing on relapsing forms of multiple sclerosis, evaluating novel therapeutic approaches and comparing treatment efficacies. Studies investigate various medications including frexalimab and remibrutinib against established treatments.

  • Relapsing MS Therapies
  • Disease Progression Analysis
  • Treatment Comparison Studies

Several trials aim to assess reduction in relapse frequency and improvement in patient outcomes.

02 Progressive MS Studies

Dedicated research into primary progressive multiple sclerosis (PPMS) and secondary progressive forms, exploring innovative treatments and their impact on disease progression. Studies evaluate higher-dose protocols and long-term effectiveness.

  • Disability Progression Markers
  • Novel Treatment Approaches
  • Long-term Safety Assessments

Focus on developing treatments to delay disability progression and improve patient mobility.

03 Advanced Therapeutic Studies

Investigation of innovative treatment modalities including BTK inhibitors and combination therapies. Research includes assessment of brain remyelination and neurodegeneration markers.

  • Biomarker Analysis
  • Pharmacokinetic Studies
  • Safety Monitoring

Comprehensive evaluation of new therapeutic approaches using advanced imaging and clinical assessments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.